Financial Performance

A silent demographic cliff threatens trillions in assets. With 75% of advisors unprepared for transition, a new framework argues for legacy over exit.

Fintech Nuvion's integration with Circle's payment network leverages USDC to tackle the high costs and delays of traditional cross-border business transactions.

A new Linux Foundation report reveals AI is a net job creator in Europe, but crippling cybersecurity shortfalls and skills gaps threaten to stall progress.

Nyrstar NV is under criminal investigation for forgery and misuse of assets, a blow that threatens to unravel investor confidence and corporate integrity.

A Cayman Islands exchange is offering a headline-grabbing 60% yield on Stellar. We dissect the math, the risk, and why this is about more than just a promo.

National Bank is raising $600M with complex notes offering a 6% yield. We dissect the deal, revealing the strategic gains and the risks investors must weigh.

A recall of Target's popular baby wipes over dangerous bacteria raises critical questions about private label safety, supplier oversight, and consumer trust.

Horizon Growth's new CEO isn't just a management change; it's the final piece in a year-long transformation from a niche carbon firm to a diversified investor.

Ottawa's first national eye care strategy isn't just about health. It's a calculated investment in economic resilience and systemic stability for an aging nation.

The Stoneport Commodity ETF is liquidating after just seven months. Its story reveals the harsh, unsentimental system governing the competitive ETF market.

Digital health firm Osara Health is targeting the 'Cancer Care Cliff,' backing its new survivorship program with a validated 25:1 ROI and proven health outcomes.

Fifteen high schoolers, mentored by racing icons, turned a Harley Nightster into a track-ready beast, proving the power of hands-on technical education.

A small biotech is about to reveal data on a novel drug that could change autoimmune care. Will its bold scientific strategy pay off for patients and investors?

As Pacira BioSciences fends off an activist investor, a high-stakes proxy fight pits long-term R&D against demands for short-term returns.

A new open standard called Aliro, backed by industry giants, is set to revolutionize access control, promising a future free from proprietary walled gardens.

The insurance giant's new 'aa' rated surplus notes aren't just debt; they are a strategic move to fortify its capital fortress and fuel future growth.

Tompkins Financial is rebranding, swapping 'Community' for 'Trust.' It's more than a name change—it's a calculated strategy to redefine its market position.

With a housing announcement set for a Toronto construction site, Ottawa signals a hands-on approach. What new funding or policy will emerge from the dust?

Lennar promotes seasoned execs Jim Parker and David Grove, signaling a strategy of continuity to tackle housing market volatility and drive operational efficiency.

After its ratings were affirmed, Jordan's MEICO chose to exit AM Best's process. Is this a savvy move to cut costs or a gamble with market transparency?